Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 10, 2026British Journal of Clinical Pharmacology

Trajectory of lipid profiles in rheumatoid arthritis patients receiving tofacitinib: Evidence from the prospective CENTRA cohort

View Full Paper
Ask AI
Bookmark
Share

Key result

Tofacitinib is linked to persistent lipid elevations through 52 weeks in rheumatoid arthritis.

  • n=374

Why the study?

Does tofacitinib alter lipid profiles in patients with rheumatoid arthritis?

Population

374 patients with rheumatoid arthritis (RA) from the prospective CENTRA cohort

Comparison

Tofacitinib vs Non-exposure group (propensity score matched 1:1)

Design

Cohort

Follow-up

52 weeks

Authors

HHHong HuangPeking UniversityYGYan GengPeking UniversityYFYong FanPeking University

Discussion

Loading...

Member takes

Implication

Tofacitinib treatment in rheumatoid arthritis patients is associated with transient elevations in LDL and total cholesterol, and sustained elevations in triglycerides and HDL over 52 weeks.

Key Points

  • This study aims to investigate how lipid profiles change in rheumatoid arthritis patients receiving tofacitinib.
  • Patients were recruited from the prospective CENTRA cohort of RA patients.
  • Lipid profiles were measured at baseline, weeks 4, 12, 24, and 52.
  • Data were analyzed between tofacitinib exposure and non-exposure groups using propensity score matching.
  • After 4 weeks, triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein levels increased in tofacitinib group.
  • Total cholesterol and low-density lipoprotein levels returned to baseline at weeks 24 and 52, respectively; triglycerides and high-density lipoprotein levels remained elevated.
  • Total cholesterol was significantly higher at week 4 and continued elevated until week 24 in the tofacitinib group compared to non-exposure group.

Study Design

Type

Cohort (n=374)

Structured PICO

Does tofacitinib alter lipid profiles in patients with rheumatoid arthritis?

P
Population
374 patients with rheumatoid arthritis followed for 52 weeks to assess lipid profile trajectories after tofacitinib exposure.
E
Exposure
Tofacitinib
C
Comparator
Non-exposure group (propensity score matched 1:1)
O
Outcome
Trajectory of lipid profiles (triglyceride, total cholesterol, HDL, LDL, and ratios of TCHO/HDL and LDL/HDL) at baseline, week 4, 12, 24 and 52surrogate

Tofacitinib treatment in rheumatoid arthritis patients is associated with transient elevations in LDL and total cholesterol, and sustained elevations in triglycerides and HDL over 52 weeks.

Cite This Study

Huang et al. (2026) conducted a cohort in rheumatoid arthritis (n=374). tofacitinib vs. non-exposure group was evaluated on Trajectory of lipid profiles (TG, TCHO, HDL, LDL). Tofacitinib exposure in rheumatoid arthritis patients induced significant elevations in total cholesterol, HDL, and LDL compared to non-exposure, with TG and HDL remaining elevated at 52 weeks.

synapsesocial.com/papers/6a0020eac8f74e3340f9bce2https://doi.org/10.1002/bcp.70598
View Full Paper
Ask AI
Bookmark
Share